Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL

July 23rd 2015

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Non-Intensive Treatments for Mantle Cell Lymphoma

June 30th 2015

Treatments for Relapsed Mantle Cell Lymphoma

June 30th 2015

Upfront Treatments for Mantle Cell Lymphoma

June 30th 2015

Treating Relapsed Diffuse Large B-Cell Lymphoma

June 30th 2015

Diffuse Large B-Cell Lymphoma Treatment Regimens

June 30th 2015

Management of Refractory Follicular Lymphoma

June 30th 2015

Stem Cell Transplantation in Follicular Lymphoma

June 30th 2015

Frontline Treatments for Follicular Lymphoma

June 30th 2015

Ibrutinib in Waldenström's Macroglobulinemia

June 30th 2015

B-Cell Receptor Inhibitor Response Criteria in CLL

June 30th 2015

Emerging Strategies in CLL and Follicular Lymphoma

June 30th 2015

Ibrutinib-Associated Adverse Events

June 30th 2015

Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015

Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015

Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015

Changing Treatment Landscape in CLL

June 30th 2015

Adding Brentuximab Vedotin to R-CHOP Induces 80% Response Rate in DLBCL

June 26th 2015

Combining the CD30-directed antibody-drug conjugate brentuximab vedotin with R-CHOP yielded objective responses in 80% of patients with advanced DLBCL in a phase II trial.

Novel Combination Strategies Explored in Two Phase III NHL Studies

June 26th 2015

John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.

Cheson on Obinutuzumab's Potential for Patients With Rituximab-Refractory iNHL

June 24th 2015

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

NEXT PAGE
PREVIOUS PAGE